ASCO GI Highlights

A study of patients with advanced biliary tract cancer found that HER2 positivity is associated with poorer prognosis but that HER2-targeted therapies can improve outcomes.

In a real-world study, MDM2-amplified, TP53 wild-type disease does not appear to be a prognostic biomarker for survival.

A dose optimization study found that zanidatamab 20 mg/kg every 2 weeks is the optimal dose for patients with HER2-positive biliary tract cancer.

A real-world study demonstrated how comprehensive genomic profiling can guide treatment decisions for metastatic biliary tract cancer, suggesting the addition of immunotherapy to standard chemotherapy may worsen outcomes for patients with specific mutations.

A study using a next-generation sequencing biorepository identified specific genomic alterations that predict response and resistance to targeted therapy in biliary tract cancer patients.

A phase 2 clinical trial of tinengotinib in patients with advanced cholangiocarcinoma showed promising antitumor efficacy.

Clinical trial recruitment and retention remain challenging in bringing innovative medicines to patients. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups.

Richard Kim, MD, presented the results of a phase 2, open-label study of patients who underwent telotristat ethyl plus first-line chemotherapy for the treatment of advanced biliary tract cancer.

Junji Furuse, MD, PhD, presented the results of a phase 2 study of tasurgratinib efficacy on patients with FGFR2 fusion-positive cholangiocarcinoma following gene fusion status confirmation by fluorescence in situ hybridization.

Teresa Macarulla, MD, PhD, presented the results of 2 phase 1a/1b dose-escalation/expansion trials, studies that measured the efficacy and safety of brigimadlin in patients with advanced biliary tract cancer.